Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors

Arthritis Rheumatol. 2022 Feb;74(2):365-366. doi: 10.1002/art.41977. Epub 2022 Jan 4.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adalimumab / therapeutic use
  • Adolescent
  • Antirheumatic Agents / therapeutic use
  • Arthralgia / chemically induced
  • Arthritis, Juvenile / drug therapy*
  • BNT162 Vaccine / adverse effects*
  • BNT162 Vaccine / therapeutic use
  • COVID-19 / prevention & control*
  • Disease Progression
  • Etanercept / therapeutic use
  • Fatigue / chemically induced
  • Female
  • Headache / chemically induced
  • Humans
  • Injection Site Reaction / etiology
  • Male
  • Methotrexate / therapeutic use
  • Myalgia / chemically induced
  • SARS-CoV-2
  • Tumor Necrosis Factor Inhibitors / therapeutic use*
  • Young Adult

Substances

  • Antirheumatic Agents
  • Tumor Necrosis Factor Inhibitors
  • Adalimumab
  • BNT162 Vaccine
  • Etanercept
  • Methotrexate